AB Science partners with Skuldtech for pancreatic cancer companion Dx
This article was originally published in Clinica
Executive Summary
French biopharma firm AB Science and genomic company Skuldtech are developing a companion diagnostic which would identify patients who respond best to masitinib, AB Science's new drug therapy for pancreatic cancer. The test is based on a novel set of biomarkers that were discovered during a Phase III clinical trial evaluating the therapeutic efficacy of a combined masitinib/gemcitabine therapy with the current standard pancreatic cancer treatment of gemcitabine alone.